Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q2 2012 Earnings Presentation

31 slides from Questcor Pharmaceuticals's earnings presentation, Jul 31, 2012

  1. Slide 1: Questcor Pharmaceuticals, July 31, 2012

    NASDAQ: QCOR Exhibit 99.1 July 31, 2012 NASDAQ: QCOR

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa

  3. Slide 3: A biopharmaceutical company whose product, Acthar, helps patients with serious conditions

    3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions Questcor A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions

  4. Slide 4: Questcor Overview

    4 Flagship Product: • Profitable, cash flow positive, $135M** in cash, debt-free • 19 approved indications Key Markets*: • Nephrotic Syndrome, Multiple Sclerosis, Infantile Spasms • Several billion dollar market opportunity Strategy: • Grow Acthar sales in each key market • Developing Rheumatology a

  5. Slide 5: Strong Second Quarter Results

    5 • 314 paid NS scripts • 1,110 paid MS scripts – Up 48% YOY • 96 paid IS scripts • Record financial performance – 4,710 vials shipped, up 94% YOY – $112.5M in net sales, up 145% YOY – $0.65 GAAP EPS (diluted), up 210% YOY Strong Second Quarter Results • 314 paid NS scripts • 1,110 paid MS scripts –

  6. Slide 6: Q2-2012 Financial Results

    6 Q2 – 2012 Q2 – 2011 Q2-2012 Financial Results • Second quarter vials shipped: 4,710 • Second quarter cash flow from operations: $43.2M • Channel inventory estimated to be within the normal range • Medicaid reserves continue to appear adequate • 3,730,069 shares repurchased during Q2-2012 Record Ne

  7. Slide 7: Shipped Vials

    Shipped Vials Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11 Q4-11 Q1-12 Q2-12 =Shipped Vials ( QUESTCOR’

  8. Slide 8: Questcor Strategy - Pursue Acthar Markets

    8 Questcor Strategy - Pursue Acthar Markets Nephrotic Syndrome (NS) Multiple Sclerosis (MS) Infantile Spasms (IS) Rheumatology Nephrotic Syndrome (NS) Multiple Sclerosis (MS) Infantile Spasms (IS) Rheumatology

  9. Slide 9: Acthar and Nephrotic Syndrome (NS)

    9 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Acthar is approved “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic ty

  10. Slide 10: NS Scripts - Strong Continued Growth

    10 NS Scripts-Strong Continued Growth Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the f

  11. Slide 11: Acthar and Multiple Sclerosis (MS)

    11 Neurodegenerative disorder Acute treatment for relapses Acthar and Multiple Sclerosis (MS) ACTHAR is approved for MS exacerbations, without reference to first line or second line use but is generally positioned as second line as a matter of marketing strategy. See for specific label information.

  12. Slide 12: MS Scripts - Record of Consistent Growth

    12 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely re

  13. Slide 13: Acthar and Infantile Spasms (IS)

    13 • Devastating, refractory form of childhood epilepsy • Unsuccessful treatment may leave infant with permanent developmental disabilities • Ultra-rare orphan disorder • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions Acthar and Infantile Spasms (IS) • Devastati

  14. Slide 14: Rheumatology

    14 • 4 key indications on the Acthar label* – Polymyositis/Dermatomyositis (PM/DM) – Systemic lupus erythematosus (Lupus) – Psoriatic arthritis – Rheumatoid arthritis • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Significant patient population (multi $B oppo

  15. Slide 15: Rheumatology: Estimated Patient Populations

    Rheumatology: Estimated Patient Populations* Indication Total Estimated US Population Estimated Target Acthar Population 15 *Questcor estimates Dermatomyositis/Polymyositis 66K ~26K Systemic Lupus Erythematosus 250K ~50K-100K Rheumatoid Arthritis 1.3M ~50K Psoriatic Arthritis 500K ~40K Juvenile Rheu

  16. Slide 16: How Does Acthar Work?

    16 How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds

  17. Slide 17: Biosimilar Pathway Difficult/Impossible

    17 • Difficult/impossible to reverse engineer ACTHAR – Not well characterized • Complex pharmacology – Not well characterized • Clinical trial(s) required • Branded competition in specific indication possible at some point in the future Biosimilar Pathway Difficult/Impossible • Difficult/impossible

  18. Slide 18: Understanding Acthar: science of how it works and clinical use

    18 • Understanding the biological properties of Acthar – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory • On-label indications – Proteinuria in NS, MS flares, Lupus • New indications – Nephrology (eg, diabetic nephropathy) – Indications with autoimmune/inf

  19. Slide 19: Understanding Acthar: clinical use

    19 • Clinical use of Acthar – Nonclinical research – Clinical research • On-label indications – Proteinuria in nephrotic syndrome (NS), multiple sclerosis (MS) flares, infantile spasms, lupus • Off-label indications – Diabetic nephropathy, traumatic brain injury, autism, MS maintenance treatment Aca

  20. Slide 20: Strategic Plan - Focus on the Embedded Pipeline in Acthar

    20 • Expand Nephrotic Syndrome promotion effort • Expand Multiple Sclerosis promotion effort • Maintain Infantile Spasm promotion effort • Initiate pilot Rheumatology promotion activity • Develop other markets for Acthar – Acthar is its own pipeline with many on-label and new indications – Further d

  21. Slide 21: Sales Force Expansion - Outlook for 2012

    21 Sales Force Expansion- Outlook for 2012 Q1-12 Q2 Q3 Q4 Q1-13 Rheumatology Sales Pilot Rheumatology Sales Pilot Neuro Hiring Neuro Hiring & Training & Training From 77 to From 77 to 107 reps 107 reps Neuro Neuro Sizing & Sizing & Alignment Alignment Neph Hiring & Neph Hiring & Training Training Fr

  22. Slide 22: Questcor is Cash Flow Positive

    22 Questcor is Cash Flow Positive Debt-free balance sheet *After return of $303 million of cash to shareholders through share repurchases. 07/27/12 Cash / ST Investments $135M* Accounts Receivable $61M Debt-free balance sheet *After return of $303 million of cash to shareholders through share repurc

  23. Slide 23: Share Repurchases: 20.9 Million Shares

    23 • 2.2 Million Preferred share buyback • 18.7 Common share buyback • $303 million returned to shareholders in stock buybacks – Average repurchase price per share: $14.50 • 58.7 million shares currently outstanding • 5.0 million share added to buyback authorization • 3.7 million shares remain on bu

  24. Slide 24: 2012 Repurchase Activity

    24 • 5.5M shares repurchased during 2012, driven by: – Sales/EPS increase – NS market traction – Sales force expansion – Rheumatology opportunity 2012 Repurchase Activity Repurchased shares significantly improved EPS Q2-2012 EPS accretion from share repurchase from 2008 through 6/30/2012: 30% • 5.5M

  25. Slide 25: Investment Highlights

    25 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in l

  26. Slide 26: Appendix

    NASDAQ: QCOR July 31, 2012 NASDAQ: QCOR

  27. Slide 27: Acthar History

    Acthar History 2000 2010 27 1950 1968-1973 DESI review = steroid label > 50 indications 1978 MS indication added 2001-2003 Questcor acquires Acthar Gel (MR), FDA approves manufacturing 2010 Infantile spasms approved, Label modernized steroid & 19 indications 2009-Present Expanding Acthar Gel (MR) re

  28. Slide 28: ACTH is a Melanocortin Peptide Derived from POMC

    28 ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary

  29. Slide 29: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

    29 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt

  30. Slide 30: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes (cont.)

    30 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC

  31. Slide 31: MOA of Acthar in NS

    MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides

Questcor Pharmaceuticals — Q2 2012 Earnings Presentation on 6ix